avian
coronaviru
caus
infecti
bronchiti
ib
one
seriou
diseas
affect
avian
industri
worldwid
howev
effect
strategi
control
ib
viru
ibv
present
therefor
develop
novel
antivir
treatment
strategi
urgent
requir
report
astragalu
polysaccharid
ap
potenti
antivir
effect
sever
virus
howev
antivir
effect
ap
ibv
remain
unclear
studi
explor
whether
ap
potenti
inhibit
ibv
infectionbi
util
sever
vitro
experiment
approach
end
effect
ap
replic
ibv
examin
chicken
embryo
kidney
cek
cell
viral
titer
calcul
use
plaqu
format
assay
cytotox
ap
test
util
cell
count
assay
express
viral
mrna
cytokin
mrna
transcript
determin
realtim
quantit
rtpcr
qrtpcr
ibv
titer
infect
cek
cell
treat
ap
significantli
reduc
dosedepend
manner
indic
ap
inhibit
ibv
replic
vitro
also
found
decreas
viral
replic
ap
treatment
associ
reduc
mrna
level
cytokin
conclus
result
suggest
ap
exhibit
antivir
activ
ibv
may
repres
potenti
therapeut
agent
inhibit
replic
ibv
avian
infecti
bronchiti
viru
ibv
member
coronavirida
famili
caus
mildtoacut
respiratori
diseas
chicken
lead
huge
econom
lossesin
poultri
industri
worldwid
serotyp
ibv
document
sinc
first
viru
isol
bird
exhibit
respiratori
symptom
unit
state
extens
genet
divers
ibv
strain
worldwid
render
vaccin
larg
ineffect
poor
crossprotect
differ
ibv
serotyp
thu
find
effect
antivir
drug
agent
imper
prevent
ibv
infect
chines
govern
prohibit
use
antivir
drug
food
anim
china
thu
util
tradit
antivir
herb
remain
major
focu
sever
report
confirm
tradit
chines
herb
effect
inhibit
replic
variou
virus
astragalu
polysaccharid
ap
isol
tradit
chines
medicin
herb
astragalu
mongholicu
wide
use
immunopotenti
recent
sever
studi
shown
supplement
ap
inhibit
replic
sever
anim
virus
includ
avian
influenza
viru
foot
mouth
diseas
viru
newcastl
diseas
viru
infecti
bursal
diseas
viru
howev
effect
ap
ibv
replic
remain
unclear
therefor
studi
investig
antivir
effect
ofap
ibv
util
sever
vitro
approach
serum
fb
hyclon
logan
ut
usa
unitsml
penicillin
streptomycin
mm
lglutamin
humidifi
chamber
supplement
co
ap
net
content
brought
sihai
plant
extract
co
ltd
nantong
china
dissolv
deioniz
water
dilut
ap
solut
steril
heat
treatment
min
store
use
cytotox
determin
use
cell
count
donjindo
japan
accord
manufactur
instruct
briefli
cek
cell
seed
cultur
plate
densiti
cellswel
incub
co
incub
h
wash
pb
three
time
ap
variou
concentr
ad
well
cell
cultur
h
mocktreat
cell
serv
control
wash
pb
cek
cell
incub
solut
h
absorb
measur
nm
use
quantunivers
micropl
spectrophotomet
biotek
instrument
inc
winooski
vt
usa
rel
cell
viabil
rate
determin
concentr
base
follow
formula
od
drug
od
control
ap
concentr
cytostat
concentr
cc
defin
nontox
concentr
calcul
viral
titer
infect
plaqueform
assay
perform
briefli
cek
cell
seed
well
tissu
cultur
dish
grown
confluenc
inocul
serial
dilut
ibv
subsequ
overlay
medium
lowmeltingpoint
agaros
dmem
contain
fb
ad
well
incub
co
h
cell
subsequ
stain
gentian
violet
crystal
violet
formaldehyd
etoh
pb
viru
titer
determin
count
number
plaqu
form
specif
dilut
describ
dove
et
al
analyz
effect
ap
infect
cell
cek
cell
monolay
infect
ibv
plaqueform
unitsml
subsequ
incub
h
cell
monolay
wash
three
time
pb
infect
cell
treat
variou
concentr
ap
mock
cell
infect
cell
repres
neg
posit
control
respect
h
cek
cell
lysat
prepar
subsequ
plaqu
assay
genom
subgenom
rna
level
ibv
mock
virusinfect
cek
cell
treat
differ
concentr
ap
quantifi
taqman
realtim
rtpcr
describ
previous
quantifi
express
cytokin
total
rna
extract
cultur
cell
use
trizol
reagent
takara
biotechnolog
dalian
china
accord
manufactur
instruct
total
rna
puriti
concentr
measur
use
ultraviolet
spectrophotometri
life
technolog
carlsbad
ca
usa
isol
rna
digest
takara
biotechnolog
dalian
china
min
cdna
synthes
total
rna
use
primescript
rt
reagent
kit
takara
amplif
perform
cdna
ina
total
volum
use
sybr
green
realtim
pcr
mastermix
roch
mortlak
australia
fast
realtim
pcr
system
appli
biosystem
shanghai
china
accord
manufactur
instruct
primer
cytokin
gene
gapdh
use
studi
list
tabl
cytokin
gene
express
normal
gapdh
use
method
total
protein
extract
cultur
cek
cell
use
modifi
radioimmunoprecipit
assay
buffer
supplement
proteas
inhibitor
cocktail
beyotim
shanghai
china
protein
concentr
determin
use
bca
protein
assay
kit
pierc
rockford
il
usa
equal
amount
protein
separ
sd
polyacrylamid
gel
electrotransf
gel
polyvinyliden
fluorid
pvdf
membran
amersham
bioscienc
usa
block
nonfat
milk
pb
membran
probe
chicken
antinucleocapsid
polyclon
antibodi
dilut
chicken
antigapdh
polyclon
antibodi
dilut
overnight
follow
incub
horseradish
peroxidaseconjug
secondari
antibodi
h
room
temperatur
gapdh
use
intern
load
control
protein
band
detect
use
chemiluminesc
substrat
kit
millipor
compani
bedford
usa
accord
manufactur
instruct
result
repres
mean
standard
deviat
sd
least
three
independ
experi
statist
analysi
perform
use
spss
softwar
packag
spss
inc
chicago
il
usa
oneway
anova
bonferronisposthoc
test
perform
compar
differ
among
three
group
differ
consid
signific
investig
whether
ap
treatment
affect
cell
viabil
toxic
ap
oncek
cell
determin
use
method
concentr
cek
cell
kill
h
respect
fig
ap
kill
cell
wherea
viabil
treatment
ap
result
indic
ap
influenc
cell
viabil
concentr
therefor
concentr
chosen
maximum
concentr
ap
antivir
assay
antivir
activ
ap
ibv
determin
plaqu
format
assay
show
fig
viru
titer
significantli
decreas
infect
cek
cell
treat
ap
dosedepend
manner
confirm
inhibitori
effect
ap
realtim
qrtpcr
perform
measur
ibv
genom
subgenom
rna
level
mock
virusinfect
cek
cell
treat
differ
concentr
ap
genom
rna
utr
set
subgenom
mrna
utr
set
express
downregul
infect
cek
cell
treat
ap
dosedepend
manner
fig
c
data
indic
infect
cek
cell
treat
ap
exhibit
overal
reduct
viral
rna
level
determin
effect
ap
viru
protein
product
amount
nucleocapsid
n
protein
ibv
determin
western
blot
n
protein
one
abundantli
express
viralprotein
ibvinfect
cell
high
affin
viral
rna
quantit
n
protein
level
sensit
marker
viral
protein
product
studi
found
n
protein
express
decreas
infect
cek
cell
treat
ap
dosedepend
manner
fig
suggest
ap
inhibit
ibv
replic
next
determin
whether
treatment
cek
cell
ap
affect
express
cytokin
induc
ibv
infect
ap
treatment
significantli
reduc
mrna
level
upregul
ibv
infect
h
compar
mocktreat
group
fig
data
demonstr
ap
inhibit
inflammatori
respons
ibvinfect
cek
cell
decreas
express
proinflammatori
cytokin
present
multipl
serotyp
ibv
exist
new
variant
regularli
emerg
due
frequent
point
mutat
recombin
event
viral
genom
ultim
lead
vaccin
failur
therefor
develop
effect
antivir
therapi
crucial
strategi
treat
ibv
infect
show
treatment
cek
cell
ap
less
induc
signific
toxic
furthermor
inhibit
ibv
replic
cek
cell
ap
occur
dosedepend
manner
vitro
henc
ap
potenti
util
antivir
agent
ibv
ap
activ
ingredi
extract
astragalu
possess
wide
rang
medicin
benefit
immunomodulatori
antioxid
antidiabet
antitumor
antiinflammatori
b
c
realtim
qrtpcr
analysi
level
ibv
genom
rna
well
genom
subgenom
mrna
asdetermin
analysi
ibv
utr
b
c
infect
cek
cell
follow
ap
treatment
differ
mean
consid
signific
p
highli
signific
p
compar
control
group
ie
ap
concentr
western
blot
util
analyz
level
n
protein
infect
cek
cell
treat
differ
concentr
ap
differ
mean
consid
signific
p
highli
signific
p
compar
control
group
ie
ap
concentr
effect
recent
studi
shown
ap
antivir
effect
sever
virus
suggest
ap
potenti
develop
use
antivir
drug
group
recent
report
ap
could
use
adjuv
ibv
vaccin
prepar
provid
better
protect
ibv
stimul
humor
andcellular
immun
howev
remain
unclear
whether
ap
direct
inhibitori
effect
ibv
studi
found
ap
could
inhibit
ibv
replic
vitro
dosedepend
manner
addit
ap
also
regul
cytokin
express
ibv
infect
result
suggest
ap
could
inhibit
ibv
replic
well
known
proinflammatori
cytokin
play
crucial
role
avian
respiratori
diseas
progress
coordin
activ
adapt
immun
respons
enabl
host
elimin
pathogen
nii
et
al
report
express
proinflammatori
cytokin
higher
ibvinfect
group
uninfect
control
group
suggest
proinflammatori
cytokin
involv
ibv
progress
sever
report
shown
ap
could
regul
cytokin
express
variou
diseas
exampl
lv
et
al
found
treatment
ap
significantli
reduc
mrna
express
colon
tissu
mice
coliti
wang
et
al
report
administr
ap
significantli
downregul
express
p
lpstreat
cell
studi
also
found
mrna
express
significantli
downregul
follow
treatment
ibvinfect
cell
ap
suggest
ap
moder
ibvinduc
inflammatori
respons
associ
viralrepl
summari
present
studi
first
show
ap
inhibit
ibv
infect
vitro
dosedepend
manner
furthermor
lower
viral
replic
ap
treatment
associ
reduc
mrna
level
proinflammatori
cytokin
data
suggest
potenti
use
ap
antivir
agent
ibv
howev
studi
requir
elucid
mechan
action
remain
unclear
author
declar
conflict
interest
regard
public
paper
